The first of two adequate, well-controlled, short-term efficacy studies of metadoxine in children with ADHD
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Metadoxine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- 15 Nov 2017 According to an Arcturus Therapeutics media release, Alcobra merged with Arcturus Therapeutics and the combined company is named as Arcturus Therapeutics
- 30 Aug 2016 According to Alcobra media release, this study is expected to start in the fourth quarter of 2016.
- 30 Aug 2016 Planned initiation date changed from 1 Jan 2016 to 1 Oct 2016, as per Alcobra media release.